Gilead Sciences (GILD) Other Accumulated Expenses (2011 - 2026)

Gilead Sciences (GILD) has reported Other Accumulated Expenses for 12 consecutive years, with $3.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses rose 3.15% year-over-year to $3.7 billion; the trailing twelve-month figure through Jun 2026 stood at $3.7 billion (up 3.15% YoY), and the FY2025 full-year result was $4.0 billion, down 27.65% from the prior year.
• Other Accumulated Expenses advanced to $3.7 billion in Q2 2026 per GILD's latest filing, from $3.4 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $5.9 billion in Q3 2023 and bottomed at $3.4 billion in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $4.5 billion across 5 years, with a median of $4.5 billion in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses rose 12.01% in 2023, then dropped 27.65% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $4.6 billion in 2022, then advanced by 12.01% to $5.1 billion in 2023, then gained by 6.51% to $5.5 billion in 2024, then retreated by 27.65% to $4.0 billion in 2025, then decreased by 6.43% to $3.7 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $3.7 billion, $3.4 billion, and $4.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.